ClinicalTrials.gg
CompletedNCT01711866Updated Apr 7, 2014Results posted

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

A Phase 4 interventional study of Rotigotine in Advanced Idiopathic Parkinson's Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 21 sites in 5 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-04-07.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
24th of 42
87 · median 123
Started
2012
with 7 others
Phase 4
8 of 44
none open now
Registered
31st of 44
by date
Lead sponsor
5 of 44
UCB BIOSCIENCES GmbH

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 24th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 8 in phase 4, and was the 31st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previous treatment with either Pramipexole or Ropinirole.

03

Conditions studied

  • Advanced Idiopathic Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro
  • Switch
  • Dopamine agonists
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has idiopathic Parkinson's Disease of more than 3 years duration, as defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes and is without any other known or suspected cause of Parkinsonism
  • Subject has motor fluctuations
  • Subject is not satisfactorily controlled following the investigator´s assessment on a total daily dose of Pramipexole or Ropinirole
  • Subject has sleep disturbance or early morning motor impairment
  • Subject has experienced nocturia for at least 3 nights within 7 days prior to the Baseline Visit
  • Subject is taking L-dopa in combination with Benserazide or Carbidopa and has been on a stable dose of L-dopa for at least 28 days prior to the Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • Subject has had therapy with Tolcapone or Budipine
  • Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics, monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine
  • Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the 6 months prior to Baseline (Visit 2)
  • Subject has a history of significant skin to adhesive or other transdermal preparations, or recent unsolved contact dermatitis
  • Subject has a history of seizures or stroke within 1 year, or a history of myocardial infarction within the last 6 months prior to enrollment
  • Subject is pregnant or nursing, or is of but (i) not surgically sterile or (ii) not using adequate methods (including at least 1 barrier method) or (iii) not sexually abstinent or (iv) not at least 2 years
  • Subject has a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Rotigotine

    First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period. * Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours. * Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours.

    Drug: Rotigotine

Interventions

  • Rotigotine up to 16 mg / 24 hours, 4 weeks.

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit

    The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: * 0 = Side effects not assessable * 1 = No side effects * 2 = Side effects do not significantly interfere with subject's functioning * 3 = Side effects significantly interfere with the subject's functioning * 4 = Side effects outweigh therapeutic efficacy.

    Time frame: Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit

Secondary outcomes

  1. Patients Global Impressions of Change (PGIC) at the End of the Treatment Period or Early Withdrawal Visit

    The PGIC is a 7-point categorical rating scale in which the subject rates the changes in functioning over time as follows: * 1 = Very much improved * 2 = Much improved * 3 = Minimally improved * 4 = No change * 5 = Minimally worse * 6 = Much worse * 7 = Very much worse.

    Time frame: Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit

07

Results

Posted Apr 7, 2014

Participant flow

This multicenter study started to enroll subjects in September 2012 in order to enroll 87 subjects in 5 countries. Participant Flow refers to the Safety Set (SS). SS consists of all subjects who were enrolled and had at least 1 patch applied during the Treatment Period.

Participant flow — Overall Study
MilestoneRotigotine
Started87
Completed79
Not completed8
Withdrew: Noncompliant3
Withdrew: Withdrawal by subject3
Withdrew: Adverse event2

Outcome measures

PrimaryClinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit

The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: * 0 = Side effects not assessable * 1 = No side effects * 2 = Side effects do not significantly interfere with subject's functioning * 3 = Side effects significantly interfere with the subject's functioning * 4 = Side effects outweigh therapeutic efficacy.

Time frame:
Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit
Reported as:
Number · participants
Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit
participantsRotigotine
CGI Item 4 score of 158
CGI Item 4 score of 226
CGI Item 4 score of 33
CGI Item 4 score of 40
CGI Item 4 score of 3 or 43
SecondaryPatients Global Impressions of Change (PGIC) at the End of the Treatment Period or Early Withdrawal Visit

The PGIC is a 7-point categorical rating scale in which the subject rates the changes in functioning over time as follows: * 1 = Very much improved * 2 = Much improved * 3 = Minimally improved * 4 = No change * 5 = Minimally worse * 6 = Much worse * 7 = Very much worse.

Time frame:
Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit
Reported as:
Number · participants
Patients Global Impressions of Change (PGIC) at the End of the Treatment Period or Early Withdrawal Visit
participantsRotigotine
PGIC category 15
PGIC category 217
PGIC category 330
PGIC category 418
PGIC category 510
PGIC category 63
PGIC category 71
PGIC category ≥ 514
PGIC category ≥ 64

Adverse events

Collected over Adverse Events (AEs) were collected over the whole study duration from the Screening Period (Day -28 to Day -1) to the Safety Follow-up Visit (up to Day 54).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—1/87 (1.1%)30/87 (34.5%)
Most frequent serious events
Most frequent serious events
EventRotigotine
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/87
Most frequent other events
Most frequent other events
EventRotigotine
Application site pruritusGeneral disorders9/87
Application site erythemaGeneral disorders6/87
DizzinessNervous system disorders6/87
DyskinesiaNervous system disorders6/87
ErythemaSkin and subcutaneous tissue disorders5/87
PruritusSkin and subcutaneous tissue disorders5/87

Baseline characteristics

Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application.

Age, Continuous
Age, Continuous(years)Rotigotine
Mean59.5 ± 8.5
Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years60
>=65 years27
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female47
Male40
Region of Enrollment
Region of Enrollment(participants)Rotigotine
United States6
Taiwan9
Malaysia1
Singapore2
Korea, Republic of69
08

Study locations

21 sites
  • 505
    Anniston, Alabama, United States
  • 506
    Atlantis, Florida, United States
  • 508
    Miami Springs, Florida, United States
  • 502
    Atlanta, Georgia, United States
  • 501
    Dayton, Ohio, United States
  • 509
    Oklahoma City, Oklahoma, United States
  • 101
    Busan, Korea, Republic of
  • 102
    Busan, Korea, Republic of
  • 108
    Daegu, Korea, Republic of
  • 109
    Daegu, Korea, Republic of
  • 105
    Gyeonggi-Do, Korea, Republic of
  • 103
    Seoul, Korea, Republic of
  • 104
    Seoul, Korea, Republic of
  • 106
    Seoul, Korea, Republic of
  • 107
    Seoul, Korea, Republic of
  • 202
    Sarawak, Malaysia
  • 401
    Singapore, Singapore
  • 403
    Singapore, Singapore
  • 301
    Linkou, Taiwan
  • 304
    Taichung, Taiwan
  • 305
    Taipei, Taiwan
09

References and documents

Publications

  • Chung SJ, Kim JM, Kim JW, Jeon BS, Singh P, Thierfelder S, Ikeda J, Bauer L; Asia Pacific Rotigotine Switching Study Group. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study. Expert Opin Pharmacother. 2015 May;16(7):961-70. doi: 10.1517/14656566.2015.1030336. Epub 2015 Apr 6. PubMed 25846031 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2012
First posted
Oct 22, 2012
Start
Sep 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Apr 7, 2014
Last update
Apr 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01711866
Responsible party
Sponsor
First posted
Oct 22, 2012
Start date
Sep 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Apr 7, 2014
Last update
Apr 7, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion